| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Infant, Premature, Diseases | 55 | 2025 | 65 | 10.740 |
Why?
|
| Infant, Newborn | 186 | 2025 | 972 | 7.570 |
Why?
|
| Infant, Premature | 85 | 2025 | 134 | 7.420 |
Why?
|
| Gestational Age | 71 | 2025 | 200 | 4.830 |
Why?
|
| Infant Mortality | 27 | 2025 | 65 | 3.690 |
Why?
|
| Infant | 77 | 2025 | 1175 | 3.310 |
Why?
|
| Infant, Extremely Low Birth Weight | 28 | 2025 | 31 | 3.270 |
Why?
|
| Retinopathy of Prematurity | 21 | 2023 | 25 | 3.010 |
Why?
|
| Infant, Very Low Birth Weight | 25 | 2022 | 50 | 2.850 |
Why?
|
| Ductus Arteriosus, Patent | 11 | 2025 | 12 | 2.590 |
Why?
|
| Erythrocyte Transfusion | 14 | 2025 | 19 | 2.440 |
Why?
|
| Enterocolitis, Necrotizing | 18 | 2024 | 24 | 2.410 |
Why?
|
| Hospital Mortality | 20 | 2022 | 210 | 2.340 |
Why?
|
| Premature Birth | 10 | 2024 | 95 | 2.210 |
Why?
|
| Bronchopulmonary Dysplasia | 17 | 2024 | 26 | 2.170 |
Why?
|
| Intensive Care Units, Neonatal | 18 | 2025 | 41 | 2.140 |
Why?
|
| Humans | 209 | 2025 | 43102 | 1.960 |
Why?
|
| Anemia, Neonatal | 6 | 2025 | 6 | 1.920 |
Why?
|
| Female | 157 | 2025 | 24698 | 1.910 |
Why?
|
| Anemia | 6 | 2025 | 55 | 1.690 |
Why?
|
| Male | 141 | 2025 | 23409 | 1.680 |
Why?
|
| Intensive Care, Neonatal | 8 | 2021 | 11 | 1.560 |
Why?
|
| Pregnancy | 41 | 2025 | 1772 | 1.430 |
Why?
|
| Child Development | 15 | 2025 | 99 | 1.310 |
Why?
|
| Retrospective Studies | 52 | 2025 | 2544 | 1.290 |
Why?
|
| Developmental Disabilities | 17 | 2021 | 67 | 1.280 |
Why?
|
| Sepsis | 10 | 2021 | 90 | 1.250 |
Why?
|
| Politics | 3 | 2019 | 42 | 1.250 |
Why?
|
| Adrenal Cortex Hormones | 11 | 2025 | 64 | 1.240 |
Why?
|
| Birth Weight | 13 | 2024 | 95 | 1.200 |
Why?
|
| Body Temperature | 3 | 2018 | 35 | 1.200 |
Why?
|
| Milk, Human | 6 | 2024 | 51 | 1.190 |
Why?
|
| Hypoxia-Ischemia, Brain | 8 | 2022 | 44 | 1.140 |
Why?
|
| Glucocorticoids | 6 | 2025 | 91 | 1.110 |
Why?
|
| Hypothermia, Induced | 8 | 2022 | 27 | 1.050 |
Why?
|
| Resuscitation | 9 | 2025 | 22 | 1.010 |
Why?
|
| Intracranial Hemorrhages | 7 | 2022 | 28 | 0.980 |
Why?
|
| Authoritarianism | 1 | 2025 | 2 | 0.950 |
Why?
|
| Social Dominance | 1 | 2025 | 6 | 0.950 |
Why?
|
| Infant, Newborn, Diseases | 8 | 2021 | 22 | 0.950 |
Why?
|
| Withholding Treatment | 4 | 2020 | 30 | 0.940 |
Why?
|
| Milrinone | 1 | 2025 | 5 | 0.940 |
Why?
|
| Prospective Studies | 32 | 2025 | 1600 | 0.940 |
Why?
|
| Hypothermia | 4 | 2022 | 13 | 0.930 |
Why?
|
| Critical Care | 2 | 2021 | 49 | 0.920 |
Why?
|
| Cardiotonic Agents | 1 | 2025 | 40 | 0.910 |
Why?
|
| United States | 45 | 2025 | 5205 | 0.890 |
Why?
|
| Cohort Studies | 24 | 2025 | 1759 | 0.890 |
Why?
|
| Neonatal Screening | 8 | 2020 | 25 | 0.870 |
Why?
|
| Registries | 16 | 2022 | 437 | 0.850 |
Why?
|
| Delivery, Obstetric | 3 | 2015 | 48 | 0.840 |
Why?
|
| Family | 3 | 2025 | 195 | 0.830 |
Why?
|
| Treatment Outcome | 22 | 2025 | 1604 | 0.820 |
Why?
|
| Erythropoietin | 2 | 2023 | 38 | 0.820 |
Why?
|
| Postoperative Complications | 1 | 2025 | 263 | 0.800 |
Why?
|
| Tocopherols | 2 | 2013 | 65 | 0.800 |
Why?
|
| Risk Factors | 31 | 2021 | 3994 | 0.790 |
Why?
|
| Patient Discharge | 8 | 2023 | 128 | 0.780 |
Why?
|
| Practice Guidelines as Topic | 7 | 2021 | 223 | 0.770 |
Why?
|
| Parenteral Nutrition | 3 | 2021 | 15 | 0.740 |
Why?
|
| Blood Transfusion | 2 | 2023 | 31 | 0.740 |
Why?
|
| Social Sciences | 2 | 2018 | 6 | 0.720 |
Why?
|
| Respiratory Distress Syndrome, Newborn | 8 | 2021 | 20 | 0.710 |
Why?
|
| Fetal Growth Retardation | 1 | 2022 | 53 | 0.710 |
Why?
|
| Survival Rate | 17 | 2021 | 355 | 0.680 |
Why?
|
| Breast Feeding | 6 | 2023 | 126 | 0.680 |
Why?
|
| Twins | 4 | 2025 | 19 | 0.670 |
Why?
|
| Culture | 2 | 2018 | 172 | 0.660 |
Why?
|
| Prenatal Exposure Delayed Effects | 8 | 2020 | 192 | 0.650 |
Why?
|
| Attitude | 2 | 2018 | 108 | 0.650 |
Why?
|
| Neonatology | 3 | 2016 | 7 | 0.630 |
Why?
|
| Vitamins | 3 | 2021 | 81 | 0.630 |
Why?
|
| Randomized Controlled Trials as Topic | 6 | 2025 | 375 | 0.630 |
Why?
|
| Cause of Death | 5 | 2018 | 186 | 0.610 |
Why?
|
| Intestinal Perforation | 5 | 2022 | 11 | 0.610 |
Why?
|
| Oxygen Inhalation Therapy | 6 | 2022 | 17 | 0.600 |
Why?
|
| Follow-Up Studies | 22 | 2025 | 1067 | 0.590 |
Why?
|
| Leukomalacia, Periventricular | 7 | 2020 | 7 | 0.590 |
Why?
|
| Hemoglobins | 7 | 2025 | 113 | 0.570 |
Why?
|
| Child, Preschool | 15 | 2025 | 1546 | 0.570 |
Why?
|
| Brain | 10 | 2022 | 1472 | 0.570 |
Why?
|
| Vitamin A | 2 | 2021 | 86 | 0.560 |
Why?
|
| Prenatal Care | 8 | 2025 | 93 | 0.560 |
Why?
|
| Chromatography, High Pressure Liquid | 5 | 2013 | 465 | 0.560 |
Why?
|
| Respiration, Artificial | 8 | 2022 | 44 | 0.550 |
Why?
|
| Morbidity | 9 | 2022 | 97 | 0.550 |
Why?
|
| Pregnancy Outcome | 4 | 2020 | 102 | 0.550 |
Why?
|
| Hypericum | 2 | 2007 | 4 | 0.530 |
Why?
|
| Herb-Drug Interactions | 2 | 2007 | 5 | 0.530 |
Why?
|
| Hematocrit | 5 | 2014 | 26 | 0.530 |
Why?
|
| Temporal Arteries | 1 | 2017 | 3 | 0.530 |
Why?
|
| Plant Preparations | 2 | 2007 | 24 | 0.520 |
Why?
|
| Child | 16 | 2024 | 3443 | 0.520 |
Why?
|
| Supine Position | 1 | 2016 | 6 | 0.510 |
Why?
|
| Prone Position | 1 | 2016 | 5 | 0.510 |
Why?
|
| Adult | 31 | 2025 | 13872 | 0.510 |
Why?
|
| Environment | 1 | 2018 | 149 | 0.500 |
Why?
|
| Survivors | 3 | 2022 | 152 | 0.490 |
Why?
|
| Cognition | 6 | 2024 | 473 | 0.460 |
Why?
|
| Romania | 4 | 2017 | 7 | 0.460 |
Why?
|
| Double-Blind Method | 7 | 2025 | 317 | 0.460 |
Why?
|
| Pregnancy in Adolescence | 1 | 2015 | 34 | 0.460 |
Why?
|
| Continuous Positive Airway Pressure | 6 | 2021 | 15 | 0.460 |
Why?
|
| Energy Metabolism | 1 | 2016 | 187 | 0.460 |
Why?
|
| Length of Stay | 8 | 2025 | 229 | 0.460 |
Why?
|
| Dehydration | 1 | 2014 | 23 | 0.440 |
Why?
|
| Risk Assessment | 11 | 2024 | 863 | 0.440 |
Why?
|
| Ibuprofen | 3 | 2023 | 34 | 0.440 |
Why?
|
| Anti-Inflammatory Agents, Non-Steroidal | 3 | 2017 | 146 | 0.440 |
Why?
|
| Time Factors | 15 | 2025 | 1857 | 0.440 |
Why?
|
| Indomethacin | 5 | 2023 | 25 | 0.430 |
Why?
|
| Logistic Models | 17 | 2020 | 1009 | 0.430 |
Why?
|
| Erythrocyte Volume | 2 | 2013 | 4 | 0.430 |
Why?
|
| Sex Factors | 8 | 2025 | 1028 | 0.430 |
Why?
|
| alpha-Tocopherol | 2 | 2013 | 27 | 0.420 |
Why?
|
| Vitamin E Deficiency | 1 | 2013 | 2 | 0.420 |
Why?
|
| Inositol | 4 | 2021 | 20 | 0.410 |
Why?
|
| Intubation, Intratracheal | 4 | 2021 | 23 | 0.410 |
Why?
|
| Oxygen | 7 | 2022 | 218 | 0.410 |
Why?
|
| Life Support Care | 3 | 2020 | 8 | 0.400 |
Why?
|
| Water-Electrolyte Balance | 2 | 2025 | 18 | 0.400 |
Why?
|
| National Institute of Child Health and Human Development (U.S.) | 7 | 2023 | 7 | 0.400 |
Why?
|
| Aftercare | 2 | 2023 | 22 | 0.390 |
Why?
|
| Stillbirth | 3 | 2024 | 20 | 0.380 |
Why?
|
| Language Disorders | 1 | 2012 | 8 | 0.370 |
Why?
|
| Incidence | 14 | 2024 | 1078 | 0.360 |
Why?
|
| Biomedical Research | 2 | 2016 | 502 | 0.360 |
Why?
|
| Fetal Blood | 2 | 2014 | 48 | 0.360 |
Why?
|
| Young Adult | 12 | 2025 | 5080 | 0.360 |
Why?
|
| Cerebral Palsy | 6 | 2024 | 14 | 0.350 |
Why?
|
| Memory Disorders | 1 | 2012 | 77 | 0.350 |
Why?
|
| Fetal Viability | 3 | 2021 | 6 | 0.350 |
Why?
|
| Placental Circulation | 1 | 2011 | 1 | 0.340 |
Why?
|
| Attitude of Health Personnel | 1 | 2013 | 231 | 0.340 |
Why?
|
| Age Factors | 7 | 2020 | 1154 | 0.340 |
Why?
|
| Anti-Bacterial Agents | 7 | 2021 | 432 | 0.340 |
Why?
|
| Bilirubin | 1 | 2010 | 18 | 0.330 |
Why?
|
| Interleukin-10 | 2 | 2010 | 87 | 0.330 |
Why?
|
| Parturition | 1 | 2010 | 22 | 0.330 |
Why?
|
| Calcitonin | 1 | 2010 | 5 | 0.320 |
Why?
|
| Rehabilitation, Vocational | 1 | 2010 | 1 | 0.320 |
Why?
|
| Receptors, IgG | 1 | 2010 | 53 | 0.320 |
Why?
|
| Protein Precursors | 1 | 2010 | 59 | 0.320 |
Why?
|
| Blindness | 1 | 2010 | 19 | 0.310 |
Why?
|
| Multicenter Studies as Topic | 3 | 2025 | 61 | 0.310 |
Why?
|
| Iowa | 6 | 2025 | 10 | 0.310 |
Why?
|
| Adolescent | 7 | 2025 | 6081 | 0.310 |
Why?
|
| Neutrophils | 1 | 2010 | 145 | 0.300 |
Why?
|
| Prognosis | 10 | 2022 | 861 | 0.290 |
Why?
|
| Nervous System Diseases | 4 | 2014 | 77 | 0.290 |
Why?
|
| Employment | 1 | 2010 | 86 | 0.290 |
Why?
|
| Infant Formula | 3 | 2024 | 17 | 0.290 |
Why?
|
| Ligation | 3 | 2025 | 12 | 0.290 |
Why?
|
| Apnea | 2 | 2025 | 8 | 0.290 |
Why?
|
| Internship and Residency | 1 | 2010 | 146 | 0.290 |
Why?
|
| Polymorphism, Single Nucleotide | 4 | 2021 | 863 | 0.290 |
Why?
|
| Infant Equipment | 2 | 2018 | 2 | 0.280 |
Why?
|
| Incubators, Infant | 2 | 2018 | 3 | 0.280 |
Why?
|
| Twins, Dizygotic | 2 | 2025 | 9 | 0.280 |
Why?
|
| Twins, Monozygotic | 2 | 2025 | 10 | 0.280 |
Why?
|
| Cardiopulmonary Resuscitation | 2 | 2018 | 24 | 0.280 |
Why?
|
| Cross-Cultural Comparison | 2 | 2018 | 111 | 0.280 |
Why?
|
| Magnesium Sulfate | 2 | 2020 | 5 | 0.270 |
Why?
|
| Prednisolone | 1 | 2007 | 16 | 0.270 |
Why?
|
| Prednisone | 1 | 2007 | 31 | 0.270 |
Why?
|
| Streptococcal Infections | 2 | 2022 | 37 | 0.270 |
Why?
|
| Maternal Age | 5 | 2025 | 33 | 0.270 |
Why?
|
| Drug Administration Schedule | 4 | 2020 | 153 | 0.270 |
Why?
|
| Genotype | 3 | 2018 | 800 | 0.260 |
Why?
|
| Hematinics | 2 | 2025 | 9 | 0.260 |
Why?
|
| Enteral Nutrition | 2 | 2019 | 17 | 0.260 |
Why?
|
| Severity of Illness Index | 6 | 2020 | 719 | 0.250 |
Why?
|
| Infant, Small for Gestational Age | 5 | 2018 | 19 | 0.250 |
Why?
|
| Seizures | 2 | 2021 | 79 | 0.250 |
Why?
|
| Early Termination of Clinical Trials | 2 | 2016 | 2 | 0.250 |
Why?
|
| Patient Selection | 2 | 2021 | 205 | 0.250 |
Why?
|
| Vaccinia virus | 2 | 2014 | 13 | 0.250 |
Why?
|
| Case-Control Studies | 8 | 2021 | 1285 | 0.240 |
Why?
|
| Escherichia coli Infections | 2 | 2020 | 45 | 0.240 |
Why?
|
| Citrates | 1 | 2025 | 18 | 0.230 |
Why?
|
| Cerebral Hemorrhage | 3 | 2020 | 104 | 0.230 |
Why?
|
| Caffeine | 1 | 2025 | 28 | 0.230 |
Why?
|
| Betamethasone | 1 | 2025 | 3 | 0.230 |
Why?
|
| Lactobacillus acidophilus | 1 | 2005 | 3 | 0.230 |
Why?
|
| Bifidobacterium | 1 | 2005 | 4 | 0.230 |
Why?
|
| Infectious Disease Transmission, Vertical | 1 | 2025 | 74 | 0.220 |
Why?
|
| Decision Making | 2 | 2018 | 249 | 0.220 |
Why?
|
| Problem-Based Learning | 2 | 2015 | 42 | 0.220 |
Why?
|
| Methicillin-Resistant Staphylococcus aureus | 2 | 2018 | 67 | 0.220 |
Why?
|
| Magnetic Resonance Imaging | 5 | 2020 | 587 | 0.220 |
Why?
|
| Neuropsychological Tests | 4 | 2017 | 284 | 0.210 |
Why?
|
| Odds Ratio | 5 | 2020 | 587 | 0.210 |
Why?
|
| Probiotics | 1 | 2005 | 37 | 0.210 |
Why?
|
| Education, Pharmacy | 2 | 2015 | 57 | 0.210 |
Why?
|
| Pregnancy Trimester, First | 1 | 2024 | 20 | 0.210 |
Why?
|
| Down Syndrome | 3 | 2014 | 32 | 0.210 |
Why?
|
| Oximetry | 4 | 2021 | 11 | 0.210 |
Why?
|
| Hydrocortisone | 2 | 2022 | 93 | 0.210 |
Why?
|
| Germany | 3 | 2019 | 26 | 0.210 |
Why?
|
| Pregnancy Complications, Infectious | 1 | 2025 | 117 | 0.210 |
Why?
|
| Socioeconomic Factors | 2 | 2018 | 1234 | 0.210 |
Why?
|
| Students, Pharmacy | 2 | 2015 | 58 | 0.210 |
Why?
|
| Pulmonary Surfactants | 5 | 2021 | 33 | 0.210 |
Why?
|
| Reticulocytes | 1 | 2023 | 9 | 0.200 |
Why?
|
| Viral Envelope Proteins | 1 | 2004 | 91 | 0.200 |
Why?
|
| Anemia, Iron-Deficiency | 1 | 2023 | 20 | 0.200 |
Why?
|
| Spectroscopy, Near-Infrared | 1 | 2023 | 25 | 0.200 |
Why?
|
| Escherichia coli | 2 | 2020 | 460 | 0.200 |
Why?
|
| Central Nervous System Stimulants | 1 | 2025 | 180 | 0.200 |
Why?
|
| Chorioamnionitis | 3 | 2025 | 5 | 0.200 |
Why?
|
| Chromosome Disorders | 2 | 2014 | 8 | 0.200 |
Why?
|
| Infant, Low Birth Weight | 3 | 2021 | 36 | 0.190 |
Why?
|
| Membrane Glycoproteins | 1 | 2004 | 224 | 0.190 |
Why?
|
| Educational Status | 4 | 2015 | 339 | 0.190 |
Why?
|
| Sex Characteristics | 2 | 2021 | 258 | 0.190 |
Why?
|
| Steroids | 1 | 2022 | 45 | 0.190 |
Why?
|
| Parents | 2 | 2018 | 370 | 0.190 |
Why?
|
| Body Mass Index | 2 | 2024 | 925 | 0.180 |
Why?
|
| Psychomotor Performance | 3 | 2014 | 159 | 0.180 |
Why?
|
| Energy Intake | 2 | 2021 | 164 | 0.180 |
Why?
|
| Rewarming | 1 | 2021 | 1 | 0.180 |
Why?
|
| Insulin | 3 | 2023 | 258 | 0.180 |
Why?
|
| Laparotomy | 1 | 2021 | 3 | 0.180 |
Why?
|
| Drainage | 1 | 2021 | 12 | 0.180 |
Why?
|
| Electrolytes | 1 | 2021 | 30 | 0.180 |
Why?
|
| Wechsler Scales | 2 | 2012 | 7 | 0.180 |
Why?
|
| Bottle Feeding | 2 | 2019 | 16 | 0.180 |
Why?
|
| Strabismus | 1 | 2021 | 18 | 0.180 |
Why?
|
| Bacteremia | 2 | 2012 | 37 | 0.170 |
Why?
|
| Mothers | 2 | 2021 | 215 | 0.170 |
Why?
|
| Angiogenesis Inhibitors | 2 | 2019 | 62 | 0.170 |
Why?
|
| Skin Physiological Phenomena | 1 | 2021 | 10 | 0.170 |
Why?
|
| Vaccines, Attenuated | 1 | 2021 | 75 | 0.170 |
Why?
|
| Viral Vaccines | 1 | 2021 | 37 | 0.170 |
Why?
|
| Persistent Fetal Circulation Syndrome | 1 | 2020 | 1 | 0.170 |
Why?
|
| Cerebral Ventricles | 1 | 2020 | 23 | 0.160 |
Why?
|
| Tissue Donors | 1 | 2021 | 53 | 0.160 |
Why?
|
| Predictive Value of Tests | 4 | 2020 | 440 | 0.160 |
Why?
|
| Kidney | 2 | 2021 | 372 | 0.160 |
Why?
|
| Temperature | 5 | 2022 | 313 | 0.160 |
Why?
|
| Glycoprotein Hormones, alpha Subunit | 1 | 2020 | 2 | 0.160 |
Why?
|
| Pituitary Hormones | 1 | 2020 | 7 | 0.160 |
Why?
|
| Refrigeration | 1 | 2020 | 4 | 0.160 |
Why?
|
| Infant Behavior | 1 | 2020 | 6 | 0.160 |
Why?
|
| Gastrointestinal Tract | 1 | 2021 | 71 | 0.160 |
Why?
|
| Mortality | 2 | 2020 | 175 | 0.160 |
Why?
|
| Longitudinal Studies | 4 | 2025 | 1063 | 0.160 |
Why?
|
| Food Analysis | 1 | 2020 | 34 | 0.160 |
Why?
|
| Weight Loss | 2 | 2025 | 137 | 0.160 |
Why?
|
| Hormones | 1 | 2020 | 55 | 0.160 |
Why?
|
| Dexamethasone | 1 | 2020 | 55 | 0.160 |
Why?
|
| Flow Cytometry | 1 | 2021 | 411 | 0.160 |
Why?
|
| Gastrostomy | 1 | 2019 | 8 | 0.150 |
Why?
|
| Language Development | 1 | 2020 | 29 | 0.150 |
Why?
|
| Diseases in Twins | 1 | 2019 | 7 | 0.150 |
Why?
|
| Motor Skills | 1 | 2020 | 46 | 0.150 |
Why?
|
| Heart | 1 | 2021 | 184 | 0.150 |
Why?
|
| Survival Analysis | 5 | 2015 | 368 | 0.150 |
Why?
|
| Home Care Services | 1 | 2019 | 37 | 0.150 |
Why?
|
| Personality | 1 | 2019 | 55 | 0.150 |
Why?
|
| Brain Injuries | 1 | 2020 | 129 | 0.140 |
Why?
|
| Impetigo | 1 | 2018 | 1 | 0.140 |
Why?
|
| Spouses | 1 | 2018 | 38 | 0.140 |
Why?
|
| Quinolones | 1 | 2018 | 14 | 0.140 |
Why?
|
| Aminopyridines | 1 | 2018 | 26 | 0.140 |
Why?
|
| Resuscitation Orders | 1 | 2018 | 7 | 0.140 |
Why?
|
| Hydrocephalus | 1 | 2018 | 16 | 0.140 |
Why?
|
| Overweight | 1 | 2020 | 249 | 0.140 |
Why?
|
| Critical Illness | 2 | 2015 | 47 | 0.140 |
Why?
|
| Databases, Factual | 4 | 2023 | 341 | 0.140 |
Why?
|
| Streptococcus agalactiae | 2 | 2022 | 8 | 0.130 |
Why?
|
| Academic Medical Centers | 1 | 2018 | 76 | 0.130 |
Why?
|
| Weight Gain | 1 | 2018 | 139 | 0.130 |
Why?
|
| Drug Utilization | 2 | 2017 | 34 | 0.130 |
Why?
|
| Cardiovascular Diseases | 2 | 2015 | 749 | 0.130 |
Why?
|
| Axilla | 1 | 2017 | 6 | 0.130 |
Why?
|
| Thermometers | 1 | 2017 | 4 | 0.130 |
Why?
|
| Rectum | 1 | 2017 | 27 | 0.130 |
Why?
|
| Research Design | 2 | 2016 | 385 | 0.130 |
Why?
|
| Cytokines | 1 | 2021 | 678 | 0.130 |
Why?
|
| Acidosis | 2 | 2014 | 51 | 0.130 |
Why?
|
| Trisomy | 2 | 2014 | 11 | 0.130 |
Why?
|
| Calorimetry, Indirect | 1 | 2016 | 9 | 0.130 |
Why?
|
| Congenital Abnormalities | 2 | 2015 | 21 | 0.130 |
Why?
|
| Body Temperature Regulation | 1 | 2016 | 8 | 0.130 |
Why?
|
| Growth | 1 | 2016 | 11 | 0.120 |
Why?
|
| Pregnancy, Multiple | 1 | 2016 | 6 | 0.120 |
Why?
|
| Clinical Trials Data Monitoring Committees | 1 | 2016 | 1 | 0.120 |
Why?
|
| Cesarean Section | 4 | 2020 | 63 | 0.120 |
Why?
|
| Pregnancy in Diabetics | 1 | 2016 | 8 | 0.120 |
Why?
|
| Head | 1 | 2016 | 28 | 0.120 |
Why?
|
| Statistics as Topic | 1 | 2016 | 123 | 0.120 |
Why?
|
| Perinatal Care | 1 | 2015 | 14 | 0.120 |
Why?
|
| Teaching | 1 | 2015 | 59 | 0.120 |
Why?
|
| Therapeutics | 1 | 2015 | 1 | 0.120 |
Why?
|
| Perinatal Mortality | 1 | 2015 | 4 | 0.110 |
Why?
|
| Feeding Behavior | 1 | 2019 | 469 | 0.110 |
Why?
|
| Diabetes Mellitus, Type 1 | 1 | 2016 | 92 | 0.110 |
Why?
|
| Heart Defects, Congenital | 2 | 2013 | 72 | 0.110 |
Why?
|
| Health Care Surveys | 2 | 2013 | 152 | 0.110 |
Why?
|
| Molluscum contagiosum virus | 1 | 2014 | 1 | 0.110 |
Why?
|
| Pharmacology, Clinical | 1 | 2014 | 1 | 0.110 |
Why?
|
| Reassortant Viruses | 1 | 2014 | 11 | 0.110 |
Why?
|
| Reproducibility of Results | 2 | 2016 | 1081 | 0.110 |
Why?
|
| Genome-Wide Association Study | 1 | 2017 | 423 | 0.110 |
Why?
|
| DNA-Directed DNA Polymerase | 1 | 2014 | 23 | 0.110 |
Why?
|
| Healthcare Disparities | 1 | 2020 | 590 | 0.110 |
Why?
|
| Respiration Disorders | 1 | 2014 | 9 | 0.110 |
Why?
|
| Dietary Supplements | 2 | 2007 | 213 | 0.110 |
Why?
|
| Peer Group | 1 | 2015 | 177 | 0.110 |
Why?
|
| Tracheostomy | 1 | 2014 | 4 | 0.110 |
Why?
|
| Vitamin E | 2 | 2005 | 62 | 0.110 |
Why?
|
| Clinical Trials as Topic | 1 | 2016 | 259 | 0.110 |
Why?
|
| Intelligence | 1 | 2014 | 15 | 0.100 |
Why?
|
| Chromatography, Reverse-Phase | 1 | 2013 | 9 | 0.100 |
Why?
|
| Echoencephalography | 3 | 2015 | 4 | 0.100 |
Why?
|
| Pyrrolidinones | 1 | 2013 | 11 | 0.100 |
Why?
|
| Quality Control | 1 | 2013 | 42 | 0.100 |
Why?
|
| Age of Onset | 3 | 2021 | 114 | 0.100 |
Why?
|
| Central Nervous System Diseases | 1 | 2014 | 32 | 0.100 |
Why?
|
| Sensitivity and Specificity | 2 | 2018 | 611 | 0.100 |
Why?
|
| Professional-Family Relations | 1 | 2013 | 11 | 0.100 |
Why?
|
| Attitude to Death | 1 | 2013 | 23 | 0.100 |
Why?
|
| Hospitals, University | 1 | 2013 | 39 | 0.100 |
Why?
|
| Treatment Failure | 3 | 2018 | 60 | 0.100 |
Why?
|
| Limit of Detection | 1 | 2013 | 94 | 0.100 |
Why?
|
| Hypotension | 1 | 2013 | 24 | 0.100 |
Why?
|
| Hemangioma | 1 | 2013 | 7 | 0.100 |
Why?
|
| Solvents | 1 | 2013 | 113 | 0.100 |
Why?
|
| Blood Pressure | 2 | 2015 | 666 | 0.100 |
Why?
|
| Heart Diseases | 1 | 2014 | 112 | 0.100 |
Why?
|
| Informed Consent | 1 | 2013 | 35 | 0.100 |
Why?
|
| Diterpenes | 1 | 2013 | 97 | 0.100 |
Why?
|
| Growth Disorders | 1 | 2013 | 23 | 0.100 |
Why?
|
| Viral Proteins | 1 | 2014 | 190 | 0.100 |
Why?
|
| DNA, Viral | 1 | 2014 | 311 | 0.100 |
Why?
|
| Term Birth | 3 | 2018 | 9 | 0.090 |
Why?
|
| Canada | 3 | 2019 | 163 | 0.090 |
Why?
|
| Bayes Theorem | 3 | 2017 | 126 | 0.090 |
Why?
|
| Methicillin | 1 | 2012 | 4 | 0.090 |
Why?
|
| Meningitis | 1 | 2012 | 10 | 0.090 |
Why?
|
| Language Tests | 1 | 2012 | 23 | 0.090 |
Why?
|
| Curcumin | 1 | 2013 | 118 | 0.090 |
Why?
|
| Risk | 3 | 2013 | 287 | 0.090 |
Why?
|
| Terminology as Topic | 1 | 2012 | 42 | 0.090 |
Why?
|
| Short Bowel Syndrome | 1 | 2011 | 3 | 0.090 |
Why?
|
| Nervous System | 1 | 2011 | 32 | 0.090 |
Why?
|
| Infant Nutritional Physiological Phenomena | 2 | 2023 | 36 | 0.090 |
Why?
|
| Communication | 1 | 2013 | 210 | 0.090 |
Why?
|
| Triplets | 1 | 2011 | 3 | 0.090 |
Why?
|
| Multivariate Analysis | 3 | 2019 | 638 | 0.090 |
Why?
|
| Staphylococcal Infections | 1 | 2012 | 67 | 0.080 |
Why?
|
| Workload | 1 | 2010 | 25 | 0.080 |
Why?
|
| Testosterone | 2 | 2023 | 211 | 0.080 |
Why?
|
| Antifungal Agents | 1 | 2012 | 169 | 0.080 |
Why?
|
| Calcitonin Gene-Related Peptide | 1 | 2010 | 11 | 0.080 |
Why?
|
| New York | 1 | 2010 | 93 | 0.080 |
Why?
|
| Competitive Behavior | 1 | 2010 | 15 | 0.080 |
Why?
|
| Comorbidity | 2 | 2019 | 737 | 0.080 |
Why?
|
| Animals | 7 | 2021 | 16992 | 0.080 |
Why?
|
| Vocal Cord Paralysis | 1 | 2009 | 2 | 0.080 |
Why?
|
| Candidiasis | 1 | 2010 | 89 | 0.080 |
Why?
|
| Fever | 2 | 2022 | 62 | 0.080 |
Why?
|
| Memory | 1 | 2011 | 174 | 0.080 |
Why?
|
| Analysis of Variance | 1 | 2011 | 575 | 0.080 |
Why?
|
| Hearing Loss | 2 | 2020 | 16 | 0.070 |
Why?
|
| Poisson Distribution | 3 | 2014 | 44 | 0.070 |
Why?
|
| High-Frequency Ventilation | 1 | 2008 | 1 | 0.070 |
Why?
|
| Vision Disorders | 2 | 2020 | 61 | 0.070 |
Why?
|
| ATP-Binding Cassette Transporters | 2 | 2021 | 82 | 0.070 |
Why?
|
| Delivery Rooms | 2 | 2018 | 4 | 0.070 |
Why?
|
| Infusions, Intravenous | 3 | 2016 | 53 | 0.070 |
Why?
|
| Constriction | 1 | 2008 | 4 | 0.070 |
Why?
|
| Injections, Intramuscular | 2 | 2021 | 21 | 0.070 |
Why?
|
| Umbilical Cord | 1 | 2008 | 14 | 0.070 |
Why?
|
| Nicotinic Acids | 1 | 2008 | 10 | 0.070 |
Why?
|
| Carbon Dioxide | 1 | 2008 | 86 | 0.070 |
Why?
|
| Cytochrome P-450 CYP3A | 1 | 2007 | 20 | 0.070 |
Why?
|
| Plants, Medicinal | 1 | 2007 | 57 | 0.070 |
Why?
|
| Biological Availability | 2 | 2021 | 116 | 0.070 |
Why?
|
| Cytochrome P-450 Enzyme System | 1 | 2007 | 98 | 0.060 |
Why?
|
| Medical Futility | 2 | 2016 | 10 | 0.060 |
Why?
|
| Reference Values | 3 | 2011 | 211 | 0.060 |
Why?
|
| Middle Aged | 2 | 2013 | 12222 | 0.060 |
Why?
|
| Gene Frequency | 2 | 2021 | 206 | 0.060 |
Why?
|
| Cognition Disorders | 2 | 2020 | 243 | 0.060 |
Why?
|
| Erythrocyte Count | 1 | 2025 | 11 | 0.060 |
Why?
|
| Brain Damage, Chronic | 1 | 2005 | 5 | 0.060 |
Why?
|
| Baths | 1 | 2005 | 1 | 0.060 |
Why?
|
| Immersion | 1 | 2005 | 1 | 0.060 |
Why?
|
| Blood Donors | 1 | 2005 | 20 | 0.060 |
Why?
|
| Monitoring, Physiologic | 1 | 2005 | 39 | 0.060 |
Why?
|
| Methamphetamine | 1 | 2007 | 166 | 0.060 |
Why?
|
| Antineoplastic Agents | 1 | 2013 | 1019 | 0.060 |
Why?
|
| Sodium | 1 | 2025 | 102 | 0.060 |
Why?
|
| Growth Charts | 1 | 2024 | 1 | 0.060 |
Why?
|
| Smallpox Vaccine | 1 | 2004 | 2 | 0.050 |
Why?
|
| Bioterrorism | 1 | 2004 | 20 | 0.050 |
Why?
|
| Administration, Oral | 1 | 2025 | 260 | 0.050 |
Why?
|
| Neutralization Tests | 1 | 2004 | 57 | 0.050 |
Why?
|
| Immunoglobulins | 1 | 2004 | 39 | 0.050 |
Why?
|
| Hyperglycemia | 1 | 2025 | 61 | 0.050 |
Why?
|
| Mutagenesis | 1 | 2004 | 91 | 0.050 |
Why?
|
| Algorithms | 2 | 2020 | 509 | 0.050 |
Why?
|
| Linear Models | 2 | 2015 | 317 | 0.050 |
Why?
|
| Patient Readmission | 1 | 2025 | 122 | 0.050 |
Why?
|
| Regression Analysis | 2 | 2016 | 490 | 0.050 |
Why?
|
| Chromosomes, Human, Pair 13 | 2 | 2014 | 9 | 0.050 |
Why?
|
| Alabama | 1 | 2023 | 52 | 0.050 |
Why?
|
| Chromosomes, Human, Pair 18 | 2 | 2014 | 12 | 0.050 |
Why?
|
| Albumins | 1 | 2023 | 33 | 0.050 |
Why?
|
| Ferritins | 1 | 2023 | 63 | 0.050 |
Why?
|
| Aged, 80 and over | 1 | 2010 | 2853 | 0.050 |
Why?
|
| Skin Care | 1 | 2022 | 1 | 0.050 |
Why?
|
| Confidence Intervals | 2 | 2014 | 162 | 0.050 |
Why?
|
| Antibodies, Monoclonal | 1 | 2004 | 306 | 0.050 |
Why?
|
| Curriculum | 2 | 2015 | 318 | 0.050 |
Why?
|
| Asphyxia Neonatorum | 1 | 2021 | 5 | 0.050 |
Why?
|
| Antibodies, Viral | 1 | 2004 | 306 | 0.050 |
Why?
|
| Cerebrovascular Circulation | 1 | 2022 | 70 | 0.050 |
Why?
|
| Iron | 1 | 2023 | 251 | 0.040 |
Why?
|
| Ebola Vaccines | 1 | 2021 | 10 | 0.040 |
Why?
|
| Body Weight | 2 | 2018 | 429 | 0.040 |
Why?
|
| Metabolic Clearance Rate | 1 | 2021 | 30 | 0.040 |
Why?
|
| Luteinizing Hormone | 1 | 2021 | 61 | 0.040 |
Why?
|
| Chi-Square Distribution | 2 | 2012 | 236 | 0.040 |
Why?
|
| Microsomes | 1 | 2021 | 55 | 0.040 |
Why?
|
| Vaccines, Synthetic | 1 | 2021 | 80 | 0.040 |
Why?
|
| Follicle Stimulating Hormone | 1 | 2021 | 43 | 0.040 |
Why?
|
| Vero Cells | 1 | 2021 | 112 | 0.040 |
Why?
|
| Virion | 1 | 2021 | 75 | 0.040 |
Why?
|
| Ventriculoperitoneal Shunt | 1 | 2020 | 2 | 0.040 |
Why?
|
| Dilatation, Pathologic | 1 | 2020 | 10 | 0.040 |
Why?
|
| Sex Distribution | 1 | 2021 | 224 | 0.040 |
Why?
|
| Electroencephalography | 1 | 2021 | 139 | 0.040 |
Why?
|
| Feasibility Studies | 1 | 2021 | 259 | 0.040 |
Why?
|
| Vermont | 1 | 2020 | 33 | 0.040 |
Why?
|
| Biological Transport | 1 | 2021 | 204 | 0.040 |
Why?
|
| Hemodynamics | 1 | 2020 | 100 | 0.040 |
Why?
|
| Demography | 1 | 2020 | 195 | 0.040 |
Why?
|
| Feeding Methods | 1 | 2019 | 4 | 0.040 |
Why?
|
| Alleles | 1 | 2021 | 352 | 0.040 |
Why?
|
| Genetics, Behavioral | 1 | 2019 | 2 | 0.040 |
Why?
|
| Progesterone | 1 | 2020 | 121 | 0.040 |
Why?
|
| Propensity Score | 1 | 2019 | 59 | 0.040 |
Why?
|
| Disease Models, Animal | 1 | 2005 | 1596 | 0.040 |
Why?
|
| Leptin | 1 | 2020 | 118 | 0.040 |
Why?
|
| Retreatment | 1 | 2018 | 11 | 0.040 |
Why?
|
| Laser Coagulation | 1 | 2018 | 3 | 0.040 |
Why?
|
| Clinical Trials, Phase III as Topic | 1 | 2018 | 17 | 0.040 |
Why?
|
| Administration, Topical | 1 | 2018 | 39 | 0.040 |
Why?
|
| Dose-Response Relationship, Drug | 2 | 2016 | 1124 | 0.040 |
Why?
|
| Combined Modality Therapy | 1 | 2018 | 173 | 0.030 |
Why?
|
| Recurrence | 1 | 2018 | 152 | 0.030 |
Why?
|
| Self Efficacy | 1 | 2019 | 215 | 0.030 |
Why?
|
| Patient Admission | 1 | 2018 | 50 | 0.030 |
Why?
|
| Ultrasonography | 1 | 2018 | 135 | 0.030 |
Why?
|
| Vascular Endothelial Growth Factor A | 1 | 2018 | 183 | 0.030 |
Why?
|
| Staphylococcus aureus | 1 | 2018 | 94 | 0.030 |
Why?
|
| GTPase-Activating Proteins | 1 | 2017 | 29 | 0.030 |
Why?
|
| Aged | 1 | 2010 | 8214 | 0.030 |
Why?
|
| Microfilament Proteins | 1 | 2017 | 72 | 0.030 |
Why?
|
| Ion Channels | 1 | 2017 | 74 | 0.030 |
Why?
|
| Endopeptidases | 1 | 2017 | 64 | 0.030 |
Why?
|
| Forkhead Transcription Factors | 1 | 2017 | 78 | 0.030 |
Why?
|
| Clinical Protocols | 1 | 2016 | 36 | 0.030 |
Why?
|
| Universities | 1 | 2020 | 559 | 0.030 |
Why?
|
| Disease Progression | 1 | 2018 | 667 | 0.030 |
Why?
|
| Pregnancy Complications | 1 | 2017 | 140 | 0.030 |
Why?
|
| Feedback, Psychological | 1 | 2015 | 16 | 0.030 |
Why?
|
| Organ Size | 1 | 2016 | 170 | 0.030 |
Why?
|
| Problem Solving | 1 | 2015 | 38 | 0.030 |
Why?
|
| Data Interpretation, Statistical | 1 | 2016 | 125 | 0.030 |
Why?
|
| Retina | 1 | 2018 | 289 | 0.030 |
Why?
|
| Obesity | 1 | 2024 | 1151 | 0.030 |
Why?
|
| Health Services Needs and Demand | 1 | 2016 | 154 | 0.030 |
Why?
|
| Adaptor Proteins, Signal Transducing | 1 | 2017 | 213 | 0.030 |
Why?
|
| Faculty | 1 | 2015 | 105 | 0.030 |
Why?
|
| Models, Biological | 1 | 2018 | 712 | 0.030 |
Why?
|
| Anesthesia | 1 | 2014 | 16 | 0.030 |
Why?
|
| Hemorrhage | 1 | 2014 | 55 | 0.030 |
Why?
|
| Arrhythmias, Cardiac | 1 | 2014 | 42 | 0.030 |
Why?
|
| Biological Assay | 1 | 2014 | 63 | 0.030 |
Why?
|
| Prevalence | 1 | 2019 | 1612 | 0.030 |
Why?
|
| Rabbits | 1 | 2014 | 278 | 0.030 |
Why?
|
| Acute Disease | 1 | 2014 | 155 | 0.030 |
Why?
|
| Thrombosis | 1 | 2014 | 81 | 0.030 |
Why?
|
| Small Molecule Libraries | 1 | 2014 | 62 | 0.030 |
Why?
|
| Cloning, Molecular | 1 | 2014 | 314 | 0.030 |
Why?
|
| Interpersonal Relations | 1 | 2015 | 222 | 0.030 |
Why?
|
| Child Behavior Disorders | 1 | 2014 | 35 | 0.030 |
Why?
|
| Educational Measurement | 1 | 2014 | 102 | 0.030 |
Why?
|
| Polysorbates | 1 | 2013 | 11 | 0.030 |
Why?
|
| Placebos | 1 | 2013 | 41 | 0.030 |
Why?
|
| Plasmids | 1 | 2014 | 244 | 0.030 |
Why?
|
| Tomography, X-Ray Computed | 1 | 2015 | 245 | 0.030 |
Why?
|
| Drug Discovery | 1 | 2014 | 108 | 0.030 |
Why?
|
| Solubility | 1 | 2013 | 139 | 0.020 |
Why?
|
| Hungary | 1 | 2013 | 9 | 0.020 |
Why?
|
| Chemistry, Pharmaceutical | 1 | 2013 | 97 | 0.020 |
Why?
|
| Multiple Birth Offspring | 1 | 2013 | 2 | 0.020 |
Why?
|
| Rats | 2 | 2013 | 3735 | 0.020 |
Why?
|
| Polyethylene Glycols | 1 | 2013 | 108 | 0.020 |
Why?
|
| Recombinant Proteins | 1 | 2014 | 518 | 0.020 |
Why?
|
| Chromosome Aberrations | 1 | 2013 | 61 | 0.020 |
Why?
|
| Hydrogen-Ion Concentration | 1 | 2014 | 388 | 0.020 |
Why?
|
| Belgium | 1 | 2012 | 4 | 0.020 |
Why?
|
| Argentina | 1 | 2012 | 14 | 0.020 |
Why?
|
| Netherlands | 1 | 2012 | 14 | 0.020 |
Why?
|
| Italy | 1 | 2012 | 27 | 0.020 |
Why?
|
| Erythrocyte Indices | 1 | 2012 | 14 | 0.020 |
Why?
|
| Spain | 1 | 2012 | 44 | 0.020 |
Why?
|
| Colombia | 1 | 2012 | 31 | 0.020 |
Why?
|
| Antiviral Agents | 1 | 2014 | 195 | 0.020 |
Why?
|
| Psychomotor Disorders | 1 | 2011 | 9 | 0.020 |
Why?
|
| Neovascularization, Pathologic | 1 | 2013 | 139 | 0.020 |
Why?
|
| Pregnancy Trimester, Second | 1 | 2011 | 15 | 0.020 |
Why?
|
| Blood-Borne Pathogens | 1 | 2011 | 7 | 0.020 |
Why?
|
| Japan | 1 | 2012 | 348 | 0.020 |
Why?
|
| Gene Expression | 1 | 2014 | 701 | 0.020 |
Why?
|
| Epithelial Cells | 1 | 2014 | 434 | 0.020 |
Why?
|
| Ethanol | 1 | 2013 | 224 | 0.020 |
Why?
|
| Cardiac Output | 1 | 2010 | 24 | 0.020 |
Why?
|
| Group II Phospholipases A2 | 1 | 2010 | 3 | 0.020 |
Why?
|
| Toll-Like Receptor 5 | 1 | 2010 | 6 | 0.020 |
Why?
|
| Primary Prevention | 1 | 2011 | 63 | 0.020 |
Why?
|
| Catheter-Related Infections | 1 | 2010 | 14 | 0.020 |
Why?
|
| Cell Line | 1 | 2014 | 1410 | 0.020 |
Why?
|
| Toll-Like Receptor 2 | 1 | 2010 | 28 | 0.020 |
Why?
|
| Apgar Score | 1 | 2010 | 5 | 0.020 |
Why?
|
| Intention to Treat Analysis | 1 | 2010 | 14 | 0.020 |
Why?
|
| Oxygen Consumption | 1 | 2010 | 110 | 0.020 |
Why?
|
| Signal Transduction | 1 | 2020 | 2157 | 0.020 |
Why?
|
| Principal Component Analysis | 1 | 2010 | 87 | 0.020 |
Why?
|
| Sutures | 1 | 2009 | 2 | 0.020 |
Why?
|
| Iatrogenic Disease | 1 | 2009 | 7 | 0.020 |
Why?
|
| Laryngoscopy | 1 | 2009 | 6 | 0.020 |
Why?
|
| Proportional Hazards Models | 1 | 2010 | 518 | 0.020 |
Why?
|
| Rats, Sprague-Dawley | 1 | 2013 | 1766 | 0.020 |
Why?
|
| Reference Standards | 1 | 2008 | 55 | 0.020 |
Why?
|
| Spectrophotometry, Ultraviolet | 1 | 2008 | 104 | 0.020 |
Why?
|
| Phenotype | 1 | 2010 | 780 | 0.020 |
Why?
|
| Drug Stability | 1 | 2008 | 129 | 0.020 |
Why?
|
| Genetic Predisposition to Disease | 1 | 2010 | 734 | 0.020 |
Why?
|
| Birth Injuries | 1 | 2005 | 7 | 0.010 |
Why?
|
| Intensive Care Units, Pediatric | 1 | 2005 | 15 | 0.010 |
Why?
|
| Hospitals, Teaching | 1 | 2005 | 33 | 0.010 |
Why?
|
| Cross-Sectional Studies | 1 | 2013 | 3156 | 0.010 |
Why?
|
| Guideline Adherence | 1 | 2005 | 98 | 0.010 |
Why?
|
| Injections, Intravenous | 1 | 2004 | 67 | 0.010 |
Why?
|